Clinical Trials Browser

OTHER × cc-486 × Other hematologic neoplasm × Clear all

NCT05141682 2026-03-03

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Phase 1/2 Active not recruiting

11 enrolled

Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

NCT04578600 2025-04-24

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Phase 1 Completed

8 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06022003 2025-03-24

OGILAR

Phase 2 Recruiting

33 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04173533 2024-05-14

AMADEUS

Phase 3 Unknown

326 enrolled

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Phase 2 Withdrawn

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute